We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Ixico Plc | LSE:IXI | London | Ordinary Share | GB00BFXR4C20 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.125 | -1.43% | 8.625 | 8.50 | 8.75 | 8.75 | 8.625 | 8.75 | 6,800 | 16:18:38 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMIXI
RNS Number : 5887Y
IXICO plc
10 May 2019
10 May 2019
IXICO plc
("IXICO" or the "Company")
Notice of Results
IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, will announce its interim results for the six months ended 31 March 2019 on Wednesday, 22 May 2019.
Giulio Cerroni, CEO and Grant Nash, CFO, will host a breakfast briefing and call for analysts at 09:00 BST on the day of the results at Cenkos Securities, 6-8 Tokenhouse Yard, London EC2R 7AS.
For further information please contact:
IXICO plc +44 (0) 20 3763 7498 Giulio Cerroni, Chief Executive Officer Cenkos Securities PLC (Nominated adviser and sole broker) +44 (0) 20 7397 8900 Giles Balleny / Max Gould (Corporate Finance) Michael F Johnson / Russell Kerr (Sales) Optimum Strategic Communications +44 (0) 203 950 9144 Mary Clark / Anne Marieke Ezendam / Supriya Mathur ixico@optimumcomms.com
About IXICO
IXICO is dedicated to delivering insights in neuroscience. Our mission is to transform the progression of our biopharmaceutical clients' neurological therapeutic pipelines through the application of novel imaging and digital biomarkers.
IXICO's data analytics services are used by the global biopharmaceutical industry to interpret data from brain scans and digital biosensors to enable better trial design, site qualification, patient selection and clinical outcomes. We provide technology-enabled services across all phases of clinical evaluation. Our integrated digital platform provides a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable clients to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new analytical techniques and companion digital health products targeted at improving patient outcomes.
More information is available on www.IXICO.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
NORDBGDUGBGBGCC
(END) Dow Jones Newswires
May 10, 2019 02:00 ET (06:00 GMT)
1 Year Ixico Chart |
1 Month Ixico Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
